Term
|
Definition
| Sodium channel blocking antiseizure drug with reduced sedative effects. Effective against tonic clonic, but not absence seizures. Stabilizes inactive state of sodium channels. Undesirable phenotypic side effects like gum enlargement, hair growth. Non linear pharmacokinetics |
|
|
Term
|
Definition
| Greater water solubility than phenyotin, effective for tonic clonic seizures for IV use. |
|
|
Term
|
Definition
| Blocks sodium channels and effective against both seizure types. Effective against a broad range of seizures and has additional activity. Inhibits glutamate release by inhibiting calcium channel and presynaptic nuerons |
|
|
Term
|
Definition
| Anti-seizure drug, inhibit T-type Ca channel, reduce pacemaker current that belies absence seizures. Weak carboxylic acid that is a clear liquid at room temp. Increase GABA by stimulating synthesis, inhibiting its breakdown. Broad effects, can treat all major seizures |
|
|
Term
|
Definition
| Inhibit the T-Type Calcium Channel in thalamus. Effective against absence seizures. Is a specific Ttype Calcium channel blocker. |
|
|
Term
|
Definition
| Barbiturate, allosteric modulate of GABAa, but in higher doses, can be an agonist. Effective for tonic clonic as it immediately depresses activity. Can lead to suppressed CNS function, sedation eventually. |
|
|
Term
|
Definition
| BDZ used for managing epilepsy, specialized for absence seizures. Indirectly inhibits Ttype Calcium currents. |
|
|
Term
|
Definition
| Antiseizure medication, management of pain, and other things. Increases biosynthesis of GABA, Gaba potentiator, Main action, binds to subunit of calcium channel, reduce current of calcium decrease NT release. |
|
|
Term
|
Definition
| Quinazolone, has sedative, hypnotic effects. |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Used to initiate and maintain general anesthesia. Potentiates GABAa receptors. Respiratory depressant, frequently produces apnea. No reversal agent other than time |
|
|
Term
|
Definition
| Binds to GABA Receptor, chloride ion influx. |
|
|
Term
|
Definition
| Has subunit a1, 2b2, and 1y2 subunit. |
|
|
Term
|
Definition
| Competitive antagonist, Decrease BDZ stimulated Cl current. Reversal agent for BDZs |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Short acting BDZ. Used against anxiety, for amnesia and hypnosis. |
|
|
Term
|
Definition
| Intermediate acting BDZ. In addition to all Midazolam does, it also is a muscle relaxant |
|
|
Term
|
Definition
| Long acting, has active metabolites |
|
|
Term
|
Definition
| Agonist of serotonin receptor, does not bind to GABAa receptors |
|
|
Term
|
Definition
| Z drug, effective at initiating sleep, but not at sustaining it. Short acting nonBDZ, increases GABA activity by binding to GABAa, can be reversed with flumazenil |
|
|
Term
|
Definition
| Normally produced in pineal gland, can be beneficial in managing insomnia, but tolerance develops quick. No convincing evidence that it can treat it |
|
|
Term
|
Definition
| Agonist of melatonin Mt1 and MT2 to promote sleep. Chronohypnotic influences SCN master clock to promote sleep. |
|
|
Term
|
Definition
| Peptides that provide signal for wakefulness. A binds OX1R and OX2R |
|
|
Term
|
Definition
| only binds OX2R, these are GPCRs |
|
|
Term
|
Definition
| Antagonist for both OX1R and OX2R, good for insomnia |
|
|
